Item 1.01 Entry Into a Material Definitive Agreement.

On August 13, 2021, the Company entered into a Sales Agreement (the "2021 Sales Agreement") with SVB Leerink LLC ("SVB Leerink") with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.0001 per share (the "Common Stock"), having an aggregate offering price of up to $50.0 million (the "Placement Shares") through SVB Leerink as its sales agent. The issuance and sale, if any, of the Placement Shares by the Company under the 2021 Sales Agreement is subject to the effectiveness of the Company's registration statement on Form S-3 (File No. 333-258783), which was filed with the Securities and Exchange Commission on August 13, 2021.

Upon delivery of a placement notice and subject to the terms and conditions of the 2021 Sales Agreement, SVB Leerink may sell the Placement Shares by any method permitted by law deemed to be an "at the market" offering as defined in Rule 415 of the Securities Act of 1933, as amended, including, without limitation, sales made through The Nasdaq Capital Market or on any other existing trading market for the Common Stock. SVB Leerink will use commercially reasonable efforts to sell the Placement Shares from time to time, based upon instructions from the Company (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company will pay SVB Leerink a commission equal to three percent (3%) of the gross sales proceeds of any Placement Shares sold through SVB Leerink under the 2021 Sales Agreement, and also has provided SVB Leerink with customary indemnification and contribution rights.

The Company is not obligated to make any sales of Common Stock under the 2021 Sales Agreement. The offering of Placement Shares pursuant to the 2021 Sales Agreement will terminate upon the earlier of (i) the sale of all Placement Shares subject to the 2021 Sales Agreement or (ii) termination of the 2021 Sales Agreement in accordance with its terms.

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Company, has issued a legal opinion relating to the Placement Shares. A copy of such legal opinion, including the consent included therein, is attached as Exhibit 5.1 hereto.

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein, nor shall there be any offer, solicitation, or sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

Item 9.01 Financial Statements and Exhibits.






Exhibit No.       Description

5.1                 Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.,
                  dated August 13, 2021 (incorporated by reference to Exhibit 5.1
                  to the Registration Statement on Form S-3 filed by the Registrant
                  on August 13, 2021, Reg. No. 333-258783).

10.1                Sales Agreement, dated August 13, 2021, by and between F-star
                  Therapeutics, Inc. and SVB Leerink LLC (incorporated by reference
                  to Exhibit 1.2 to the Registration Statement on Form S-3 filed by
                  the Registrant on August 13, 2021, Reg. No. 333-258783).

23.1                Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
                  (contained in Exhibit 5.1 above).

104               Cover page Interactive Data File (embedded within Inline XBRL
                  document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses